Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection.
Détails
Demande d'une copie Sous embargo indéterminé.Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_7192892F1CD1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection.
Périodique
European journal of physical and rehabilitation medicine
ISSN
1973-9095 (Electronic)
ISSN-L
1973-9087
Statut éditorial
Publié
Date de publication
08/2015
Peer-reviewed
Oui
Volume
51
Numéro
4
Pages
353-359
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The most important adverse effect of BoNT-A is the systemic diffusion of the toxin. There is some evidence that the administration of high doses can increase the risk of systemic diffusion and the development of clinically evident adverse effects, however an international consensus does not exist about its maximum dose.
The aim of this study was to evaluate changes in autonomic heart drive induced by high doses (higher than 600 units) of incobotulinumtoxinA injection in spastic stroke patients. Moreover, the treatment safety by monitoring adverse events occurrence was assessed.
Case control study.
Eleven stroke survivors with spastic hemiplegia.
Patients were treated with intramuscular focal injections of IncobotulinumtoxinA (NT 201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany). Doses were below 12 units/Kg. Each patient underwent an ECG recording before injection and 10 days after treatment. Linear and non-linear Heart Rate variability (HRV) measures were derived from ECGs with a dedicated software.
None of the variable considered showed statistically significant changes after BoNT-A injection.
The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be safe regarding autonomic heart drive.
The use of IncobotulinumtoxinA up to 600 units could be a safe therapeutic option in spastic hemiplegic stroke survivors.
The aim of this study was to evaluate changes in autonomic heart drive induced by high doses (higher than 600 units) of incobotulinumtoxinA injection in spastic stroke patients. Moreover, the treatment safety by monitoring adverse events occurrence was assessed.
Case control study.
Eleven stroke survivors with spastic hemiplegia.
Patients were treated with intramuscular focal injections of IncobotulinumtoxinA (NT 201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany). Doses were below 12 units/Kg. Each patient underwent an ECG recording before injection and 10 days after treatment. Linear and non-linear Heart Rate variability (HRV) measures were derived from ECGs with a dedicated software.
None of the variable considered showed statistically significant changes after BoNT-A injection.
The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be safe regarding autonomic heart drive.
The use of IncobotulinumtoxinA up to 600 units could be a safe therapeutic option in spastic hemiplegic stroke survivors.
Mots-clé
Adult, Aged, Autonomic Nervous System/drug effects, Autonomic Nervous System/physiopathology, Botulinum Toxins, Type A/administration & dosage, Botulism/complications, Botulism/microbiology, Dose-Response Relationship, Drug, Electrocardiography/drug effects, Female, Follow-Up Studies, Heart Rate/drug effects, Heart Rate/physiology, Hemiplegia/drug therapy, Hemiplegia/etiology, Hemiplegia/physiopathology, Humans, Injections, Intramuscular, Male, Middle Aged, Neurotoxins/administration & dosage, Retrospective Studies, Stroke/complications, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/02/2016 21:12
Dernière modification de la notice
23/10/2020 6:23
Données d'usage
